Business Context and Reporting Period
This Form 8-K reports on the 2019 Annual Meeting of Stockholders held by Aquestive Therapeutics, Inc. on June 13, 2019. The filing details the final voting results for director elections, auditor ratification, and the approval of the Employee Stock Purchase Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes rather than financial performance data.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Elections: Three Class I director nominees were elected to serve three-year terms until the 2022 Annual Meeting:
- Keith J. Kendall: 17,408,367 votes for; 1,134,435 votes withheld.
- Nancy S. Lurker: 17,466,503 votes for; 1,076,299 votes withheld.
- James S. Scibetta: 17,469,411 votes for; 1,073,391 votes withheld.
- Auditor Ratification: The appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was ratified with 19,987,272 votes for, 11,783 votes against, and 2,209 abstentions.
- Employee Stock Purchase Plan: The plan was approved with 17,515,891 votes for, 747,392 votes against, and 279,519 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the effective date of the newly approved Employee Stock Purchase Plan (Exhibit 10.1).
- Confirm the tenure of the newly elected Class I directors through the 2022 Annual Meeting.
- Review the full text of the Employee Stock Purchase Plan to understand eligibility and contribution limits.